

# SANTHERA PHARMACEUTICALS HOLDING AG

ISIN: CH1276028821 WKN: 127602882 Asset Class: Stock

## Company

2024/10/18 17:30:09



Price

9.19 CHF

Difference ▲ 1.55%(0.14)



## Contact Details

SANTHERA PHARMACEUTICALS  
HOLDING AG

Tel: +41-61-906-89-50

--

Fax: +41-61-906-89-51

Hohenrainstrasse 24

Web:

<http://www.santhera.com>

4133 Pratteln

E-mail:

[office@santhera.com](mailto:office@santhera.com)

## Company Profile

Santhera Pharmaceuticals Holding AG engages in the development and commercialization of products for the treatment of neuromuscular and pulmonary diseases. Its product pipeline includes Vamorolone and Lonodelestat. The company was founded by Thomas Meier in 1998 and is headquartered in Pratteln, Switzerland.

## Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2023		2022		2021	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
<b>Current assets</b>	34,657,000		3,065,000		24,641,000	
<b>Common stock capital</b>		1,262,000		753,000		54,608,000
<b>Fixed assets</b>	74,972,000		60,661,000		66,476,000	
<b>Equity capital of a company</b>		59,943,000		-43,686,000		1,328,000
<b>Cash and cash equivalents</b>	30,370,000		1,353,000		21,208,000	
<b>Accrued liabilities</b>		3,858,000		26,805,000		4,794,000
<b>Other assets</b>	-		-		-	
<b>Current liabilities</b>		44,315,000		49,414,000		32,782,000
<b>Prepayments and accrued income</b>	-		-		-	
<b>Non-current liabilities</b>		5,371,000		57,998,000		57,007,000
<b>Different income</b>		-		-		-
<b>Other liabilities</b>		0		4,335,000		20,491,000
<b>Total assets</b>	109,629,000	109,629,000	63,726,000	63,726,000	91,117,000	91,117,000

## Balance notes

	2023	2022	2021
<b>Accounting standard</b>	IFRS	IFRS	IFRS
<b>Employees</b>	45	46	43
<b>Equity ratio</b>	54.68%	-68.55%	1.46%
<b>Debt-equity ratio</b>	82.89%	-245.87%	6,761.22%

## Others

	2023	2022	2021
<b>Tax Expense Rate</b>	0.07%	-0.65%	-1.48%

# SANTHERA PHARMACEUTICALS HOLDING AG

ISIN: CH1276028821 WKN: 127602882 Asset Class: Stock

## Income statement

	2023	2022	2021
<b>Turnover</b>	103,414,000	7,473,000	-1,595,000
<b>Net income</b>	54,782,000	-71,076,000	-55,526,000
<b>EBIT</b>	80,475,755	-53,659,371	-40,749,710
<b>Operating income before taxes</b>	54,820,000	-70,616,000	-54,717,000
<b>Cash Flow</b>	47,271,000	-29,843,000	-37,359,000
<b>Net interest income</b>	-20,808,000	-20,189,000	-16,422,000
<b>Research and development expenses</b>	18,674,000	30,536,000	29,715,000
<b>Income taxes</b>	38,000	460,000	809,000
<b>Result from investments in subsidiaries, associates and other</b>	0	0	0
<b>Revenues per employee</b>	2,445,396	172,870	-39,471

## Board of Directors

Otto Schwarz	Member of the administrative board
Shabir Hasham	Member of the administrative board
Bradley Meyer	Member of the administrative board
Philipp Gutzwiller	Member of the administrative board
Thomas Meier	Chairman of the administrative board

## Members of Management Board

Dario Eklund	Chairman of Managing Board
Ana Vera	Member of Executive Committee
Andrew Smith	Member of Executive Committee
Geert Jan van Daal	Member of Executive Committee
Günther Metz	Member of Executive Committee
Neville Kodkani	Member of Executive Committee
Oliver Kronenberg	Member of Executive Committee
Andreas Missy	Member of Executive Committee
Marc Schrader	Member of Executive Committee
Oliver Strub	Member of Executive Committee
Sabine Pilot	Member of Executive Committee
Sarah Holmes-Klotz	Member of Executive Committee